Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.

Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.

Pediatr Neonatol. 2014 Oct;55(5):387-92. doi: 10.1016/j.pedneo.2013.11.007. Epub 2014 Mar 11.

2.

Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.

Tse SM, Silverman ED, McCrindle BW, Yeung RS.

J Pediatr. 2002 Apr;140(4):450-5.

PMID:
12006960
3.

Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.

Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.

Pediatrics. 2004 Dec;114(6):e689-93. Epub 2004 Nov 15.

PMID:
15545617
4.

Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.

Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.

J Med Assoc Thai. 2002 Nov;85 Suppl 4:S1121-6.

PMID:
12549785
5.

[Risk factors for coronary artery lesions in children with Kawasaki disease].

Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.

Zhongguo Dang Dai Er Ke Za Zhi. 2012 Dec;14(12):938-41. Chinese.

6.

A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.

Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F.

Pediatr Cardiol. 2015 Aug;36(6):1166-72. doi: 10.1007/s00246-015-1138-0. Epub 2015 Mar 27.

PMID:
25812827
7.

Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.

Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.

Pediatr Infect Dis J. 2008 Feb;27(2):155-60. doi: 10.1097/INF.0b013e31815922b5.

PMID:
18174868
8.

[Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].

Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.

Zhonghua Er Ke Za Zhi. 2006 Dec;44(12):891-5. Chinese.

PMID:
17254453
9.

Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease.

Dominguez SR, Anderson MS, El-Adawy M, Glodé MP.

Pediatr Infect Dis J. 2012 Dec;31(12):1217-20. doi: 10.1097/INF.0b013e318266bcf9.

PMID:
22760536
10.

Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.

Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.

J Huazhong Univ Sci Technolog Med Sci. 2005;25(3):348-50, 370.

PMID:
16201293
11.

Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.

Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H.

Pediatr Infect Dis J. 2009 Jun;28(6):498-502.

PMID:
19504733
12.

Immunoglobulin failure and retreatment in Kawasaki disease.

Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.

Pediatr Cardiol. 2003 Mar-Apr;24(2):145-8. Epub 2002 Dec 4.

PMID:
12457253
13.

Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.

Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.

Arch Dis Child. 2008 Feb;93(2):142-6. Epub 2007 Oct 25.

PMID:
17962370
14.

Hepatobiliary risk factors for clinical outcome of Kawasaki disease in children.

Yi DY, Kim JY, Choi EY, Choi JY, Yang HR.

BMC Pediatr. 2014 Feb 18;14:51. doi: 10.1186/1471-2431-14-51.

15.

Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.

Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP.

Pediatr Infect Dis J. 1998 Dec;17(12):1144-8.

PMID:
9877364
16.

Coronary involvement in infants with Kawasaki disease treated with intravenous gamma-globulin.

Moreno N, Méndez-Echevarría A, de Inocencio J, Del Castillo F, Baquero-Artigao F, García-Miguel MJ, de José MI, Aracil J.

Pediatr Cardiol. 2008 Jan;29(1):31-5. Epub 2007 Oct 5.

PMID:
17917769
17.

Treatment of Kawasaki disease using locally product intravenous immunoglobulin.

Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.

J Med Assoc Thai. 2003 Aug;86 Suppl 3:S656-60.

PMID:
14700163
18.

High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.

Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.

PLoS One. 2015 Dec 10;10(12):e0144603. doi: 10.1371/journal.pone.0144603. eCollection 2015.

19.

Assessment of risk factors for Korean children with Kawasaki disease.

Kim JJ, Hong YM, Yun SW, Han MK, Lee KY, Song MS, Lee HD, Kim DS, Sohn S, Ha KS, Hong SJ, Kim KJ, Park IS, Jang GY, Lee JK; Korean Kawasaki Disease Genetics Consortium.

Pediatr Cardiol. 2012 Apr;33(4):513-20. doi: 10.1007/s00246-011-0143-1. Epub 2011 Nov 22.

PMID:
22105492
20.

Characteristics of Kawasaki disease in older children.

Cai Z, Zuo R, Liu Y.

Clin Pediatr (Phila). 2011 Oct;50(10):952-6. doi: 10.1177/0009922811409027. Epub 2011 May 31.

PMID:
21628347
Items per page

Supplemental Content

Write to the Help Desk